FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Pharmacol Ther / Pharmacokinetics of Topical Administration of Altrenogest in...
Journal of veterinary pharmacology and therapeutics2026; doi: 10.1111/jvp.70040

Pharmacokinetics of Topical Administration of Altrenogest in Mares and Implications for Human Health.

Abstract: Altrenogest is a synthetic progestogen widely used in equine reproductive management. Adverse effects to altrenogest have been reported in people with cutaneous exposure reported as the highest exposure pathway. Despite these reports, there has been no quantitative research to determine the capacity for altrenogest to be absorbed through skin. This study aimed to determine if cutaneous application of oral altrenogest results in systemic absorption in mares and to evaluate the influence of application site. A randomized, two-period, two-treatment crossover study was undertaken in eight mares. Mares received a topical application of oral altrenogest (0.044 mg/kg) onto clipped skin on either the neck or back for five consecutive days, with blood sampling immediately before and 1 h after each treatment. Following the final dose, blood samples were taken at 0.08, 0.16, 0.3, 0.5, 0.66, 0.83, 1, 1.5, 2, 4, 6, 8, 12, 24 and 48 h. After a 3-week washout period mares underwent treatment on the alternative site, sampling at the same intervals. Plasma samples were analysed for altrenogest using LC-MS/MS and pharmacokinetic variables were estimated using noncompartmental analysis. Altrenogest was detectable in plasma following application at both sites. Peak plasma concentrations (C) were significantly higher following neck application (1.7 ± 0.7 ng/mL) compared to the back (0.6 ± 0.3 ng/mL; p = 0.002). Concentrations remained quantifiable throughout the 48-h post-treatment period. As altrenogest is absorbed through equine skin of varying thickness, there is a need for cautious use and handling, especially given that human skin is thinner than equine skin.
© 2026 The Author(s). Journal of Veterinary Pharmacology and Therapeutics published by John Wiley & Sons Ltd.
Get Full Text
Publication Date: 2026-02-26 PubMed ID: 41744272DOI: 10.1111/jvp.70040Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Cite This Article

APA
Loy J, Sornalingam K, Cawley A, Scrivener C, Keledjian J, Noble GK. (2026). Pharmacokinetics of Topical Administration of Altrenogest in Mares and Implications for Human Health. J Vet Pharmacol Ther. https://doi.org/10.1111/jvp.70040

Publication

Journal of veterinary pharmacology and therapeutics
ISSN: 1365-2885
NlmUniqueID: 7910920
Country: England
Language: English

Researcher Affiliations

Loy, Jaymie
  • School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia.
Sornalingam, Kireesan
  • Forensic and Toxicology Laboratory, NSW Heath Pathology, Sydney, Australia.
  • Australian Racing Forensic Laboratory, Racing NSW, Sydney, Australia.
Cawley, Adam
  • Racing Analytical Services Limited, Flemington, Victoria, Australia.
Scrivener, Colin
  • School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia.
Keledjian, John
  • Australian Racing Forensic Laboratory, Racing NSW, Sydney, Australia.
Noble, Glenys K
  • School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia.

Grant Funding

  • 0000102436 / Agrifutures Australia

References

This article includes 33 references
  1. Abdulaziz Alzamzami, A., M. M. A. Ibrahim, F. M. A. Nemer, et al. 2025. “Personal Protective Equipment Usage and Compliance Among Healthcare Workers.” International Journal of Community Medicine and Public Health 12, no. 2: 1016–1020. https://doi.org/10.18203/2394‐6040.ijcmph20250043.
  2. Barry, B. W. 2001. “Novel Mechanisms and Devices to Enable Successful Transdermal Drug Delivery.” European Journal of Pharmaceutical Sciences 14, no. 2: 101–114. https://doi.org/10.1016/S0928‐0987(01)00167‐1.
  3. Becker, M. H. 1974. “The Health Belief Model and Sick Role Behavior.” Health Education Monographs 2, no. 4: 409–419. https://doi.org/10.1177/109019817400200407.
  4. Bizley, S. C., J. Dudhia, R. K. W. Smith, and A. C. Williams. 2023. “Transdermal Drug Delivery in Horses: An In Vitro Comparison of Skin Structure and Permeation of Two Model Drugs at Various Anatomical Sites.” Veterinary Dermatology 34, no. 3: 235–245. https://doi.org/10.1111/vde.13162.
  5. Clavijo, R. I., and W. Hsiao. 2018. “Update on Male Reproductive Endocrinology.” Translational Andrology and Urology 7, no. Suppl 3: S367–s372. https://doi.org/10.21037/tau.2018.03.25.
  6. Ellis, K. E., R. M. Council‐Troche, K. A. Von Dollen, et al. 2019. “Pharmacokinetics of Intrarectal Altrenogest in Horses.” Journal of Equine Veterinary Science 72: 41–46. https://doi.org/10.1016/j.jevs.2018.10.001.
  7. European Medicines Agency. 2004. “Committee for Medicinal Products for Veterinary Use.” https://www.ema.europa.eu/en/documents/mrl‐report/altrenogest‐equidae‐and‐porcine‐species‐european‐public‐maximum‐residue‐limit‐assessment‐report‐epmar‐cvmp_en.pdf.
  8. Fedorka, C. E., and M. H. T. Troedsson. 2021. “The Use of Progestins in Equine Medicine: A Review.” Equine Veterinary Education 33, no. 9: 494–504. https://doi.org/10.1111/eve.13332.
  9. George, J., N. Shafqat, R. Verma, and A. B. Patidar. 2023. “Factors Influencing Compliance With Personal Protective Equipment (PPE) Use Among Healthcare Workers.” Cureus 15, no. 2: e35269. https://doi.org/10.7759/cureus.35269.
  10. Hornberger, K., C. C. Lyman, J. M. Baldrighi, and G. R. Holyoak. 2019. “Plasma Altrenogest Concentrations in Mares After Intrarectal or Intravaginal Administration.” Clinical Theriogenology 11, no. 1: 59–65. https://doi.org/10.58292/ct.v10.10015.
  11. Knych, H. K., R. M. Arthur, S. R. Gretler, D. S. McKemie, S. Goldin, and P. H. Kass. 2021. “Pharmacokinetics of Transdermal Flunixin Meglumine and Effects on Biomarkers of Inflammation in Horses.” Journal of Veterinary Pharmacology and Therapeutics 44, no. 5: 745–753. https://doi.org/10.1111/jvp.12993.
  12. Lee, Y., and K. Hwang. 2002. “Skin Thickness of Korean Adults.” Surgical and Radiologic Anatomy 24, no. 3: 183–189. https://doi.org/10.1007/s00276‐002‐0034‐5.
  13. Loy, J., A. Cawley, K. Sornalingam, C. J. Scrivener, J. Keledjian, and G. K. Noble. 2025. “Pharmacokinetics of Two Formulations of Altrenogest Administered to Mares.” Drug Testing and Analysis 17: 1034–1040. https://doi.org/10.1002/dta.3796.
  14. McConaghy, F. F., L. Black, S. Colgan, and L. H. Morris. 2016. “Studies of the Pharmacokinetic Profile, In Vivo Efficacy and Safety of Injectable Altrenogest for the Suppression of Oestrus in Mares.” Australian Veterinary Journal 94, no. 7: 248–255. https://doi.org/10.1111/avj.12459.
  15. McManus, J. M., K. Bohn, M. Alyamani, Y‐M. Chung, E. A. Klein, and N. Sharifi. 2019. “Rapid and Structure‐Specific Cellular Uptake of Selected Steroids.” PLoS One 14, no. 10: e0224081. https://doi.org/10.1371/journal.pone.0224081.
  16. McRobb, L., D. J. Handelsman, R. Kazlauskas, S. Wilkinson, M. D. McLeod, and A. K. Heather. 2008. “Structure–Activity Relationships of Synthetic Progestins in a Yeast‐Based In Vitro Androgen Bioassay.” Journal of Steroid Biochemistry and Molecular Biology 110, no. 1: 39–47. https://doi.org/10.1016/j.jsbmb.2007.10.008.
  17. Merck Sharp & Dohme Corp. 2024. “Label: Regumate ‐ Altrenogest Solution.” https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d14df1‐ec72‐46f1‐ad3b‐f90547088ff5.
  18. Mills, P. C., and S. E. Cross. 2006. “Transdermal Drug Delivery: Basic Principles for the Veterinarian.” Veterinary Journal 172, no. 2: 218–233. https://doi.org/10.1016/j.tvjl.2005.09.006.
  19. National Center for Biotechnology Information. 2025. “PubChem Compound Summary for CID 10041070, Altrenogest.” https://pubchem.ncbi.nlm.nih.gov/compound/Altrenogest.
  20. Niswender, G. D., J. L. Juengel, P. J. Silva, M. K. Rollyson, and E. W. McIntush. 2000. “Mechanisms Controlling the Function and Life Span of the Corpus Luteum.” Physiological Reviews 80, no. 1: 1–29. https://doi.org/10.1152/physrev.2000.80.1.1.
  21. Poet, T. S., and J. N. McDougal. 2002. “Skin Absorption and Human Risk Assessment.” Chemico‐Biological Interactions 140, no. 1: 19–34. https://doi.org/10.1016/S0009‐2797(02)00013‐3.
  22. Proctor, A. R. 2022. “The Occupational Health Hazards of Altrenogest.” Master's thesis, University of Iowa, Iowa Research Online.
  23. Riviere, J. E., and M. G. Papich. 2013. Veterinary Pharmacology and Therapeutics. 9th ed. Wiley.
  24. Roberts, M. S., S. E. Cross, and Y. G. Anissimov. 2004. “Factors Affecting the Formation of a Skin Reservoir for Topically Applied Solutes.” Skin Pharmacology and Physiology 17, no. 1: 3–16. https://doi.org/10.1159/000074057.
  25. Scheuplein, R. J., and I. H. Blank. 1971. “Permeability of the Skin.” Physiological Reviews 51: 702–747. https://doi.org/10.1152/physrev.1971.51.4.702.
  26. Schmook, F. P., J. G. Meingassner, and A. Billich. 2001. “Comparison of Human Skin or Epidermis Models With Human and Animal Skin in In‐Vitro Percutaneous Absorption.” International Journal of Pharmaceutics 215, no. 1: 51–56. https://doi.org/10.1016/S0378‐5173(00)00665‐7.
  27. Steffey, M. A., D. J. Griffon, M. Risselada, et al. 2023. “A Narrative Review of the Physiology and Health Effects of Burnout Associated With Veterinarian‐Pertinent Occupational Stressors.” Frontiers in Veterinary Science 10: 1184525. https://doi.org/10.3389/fvets.2023.1184525.
  28. Steffey, M. A., V. F. Scharf, M. Risselada, et al. 2023. “A Narrative Review of Occupational Scheduling That Impacts Fatigue and Recovery Relevant to Veterinarian Well‐Being.” Canadian Veterinary Journal 64, no. 7: 674–683.
  29. Talukdar, A. H., M. L. Calhoun, and A. W. Stinson. 1972. “Microscopic Anatomy of the Skin of the Horse.” American Journal of Veterinary Research 33, no. 12: 2365–2390.
  30. Tong, L., M. Stewart, I. Johnson, et al. 2020. “A Comparative Neuro‐Histological Assessment of Gluteal Skin Thickness and Cutaneous Nociceptor Distribution in Horses and Humans.” Animals 10, no. 11: 2094. https://doi.org/10.3390/ani10112094.
  31. Travison, T. G., J. E. Morley, A. B. Araujo, A. B. O'Donnell, and J. B. McKinlay. 2006. “The Relationship Between Libido and Testosterone Levels in Aging Men.” Journal of Clinical Endocrinology and Metabolism 91, no. 7: 2509–2513. https://doi.org/10.1210/jc.2005‐2508.
  32. U.S. Food and Drug Administration. 2023. “Potential Health Risks to People Exposed to Altrenogest Products for Horses or Pigs.” https://www.fda.gov/animal‐veterinary/product‐safety‐information/potential‐health‐risks‐people‐exposed‐altrenogest‐products‐horses‐or‐pigs#:~:text=Reproductive%20adverse%20effects%20reported%20in,%2C%20diarrhea%2C%20vomiting%20and%20rashes.
  33. Volkering, M. E. 2009. “Variation of Skin Thickness Over the Equine Body and the Correlation Between Skin Fold Measurement and Actual Skin Thickness.” PhD thesis.

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,034 horse owners like you who receive our email updates on horse health and nutrition.